IntelliPharmaCeutics International (TSXV:IPCI) ROCE % : 0.00% (As of Aug. 2023)

View and export this data going back to 1999. Start your Free Trial

What is IntelliPharmaCeutics International ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. IntelliPharmaCeutics International's annualized ROCE % for the quarter that ended in Aug. 2023 was 0.00%.

IntelliPharmaCeutics International ROCE % Historical Data

The historical data trend for IntelliPharmaCeutics International's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International ROCE % Chart

IntelliPharmaCeutics International Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

ROCE %

Get a 7-Day Free Trial

-305.83

-638.18

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

IntelliPharmaCeutics International ROCE % Calculation

IntelliPharmaCeutics International's annualized ROCE % for the fiscal year that ended in Nov. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Nov. 2022 )		(A: Nov. 2021 )		(A: Nov. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Nov. 2022 )		(A: Nov. 2021 )		(A: Nov. 2022 )
	=	-3.492	/	( ( (2.634 - 12.884)	+	(1.927 - 16.161) )	/ 2 )
	=	-3.492	/	( (-10.25	+	-14.234)	/ 2 )
	=	-3.492	/	-12.242
	=	28.52 %

IntelliPharmaCeutics International's ROCE % of for the quarter that ended in Aug. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Aug. 2023 )		(Q: May. 2023 )		(Q: Aug. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Aug. 2023 )		(Q: May. 2023 )		(Q: Aug. 2023 )
	=	-9.56	/	( ( (2.345 - 17.196)	+	(2.111 - 19.465) )	/ 2 )
	=	-9.56	/	( ( -14.851	+	-17.354 )	/ 2 )
	=	-9.56	/	-16.1025
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Aug. 2023) EBIT data.

IntelliPharmaCeutics International (TSXV:IPCI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

IntelliPharmaCeutics International ROCE % Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (TSXV:IPCI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (TSXV:IPCI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

IPCIF:USA I4AA:Germany

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International (TSXV:IPCI) Headlines

No Headlines